The CAV2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the CAV2 gene has been disrupted to ablate caveolin-2 protein expression. This polyclonal knockout approach generates a diverse loss-of-function model without clonal isolation, preserving natural genetic heterogeneity while eliminating target gene function. The cells are suitable for pooled phenotypic and signaling studies, providing a robust system for investigating CAV2-dependent processes in a human colorectal adenocarcinoma background.
The HT29 host cell line is derived from a human colorectal adenocarcinoma and serves as a well-characterized model of intestinal epithelium. These adherent cells display epithelial morphology and harbor a mutant p53 tumor suppressor, reflecting common oncogenic alterations in colorectal cancer. HT29 cells are extensively used to study intestinal cell biology, tumorigenesis, and drug responses, making them a relevant host for evaluating the role of caveolin-2 in colorectal cancer biology.
Caveolin-2 (CAV2) is a scaffolding protein that oligomerizes with Caveolin-1 (CAV1) to form the structural backbone of caveolae, flask-shaped plasma membrane invaginations involved in endocytosis, lipid homeostasis, and signal transduction. CAV2 expression is regulated by CAV1, FOXA1, GATA6, STAT3, and cholesterol levels. The protein interacts directly with CAV1, Cavin-1, integrin beta1, EGFR, Src, and heterotrimeric G-proteins to organize signaling complexes. Disruption of CAV2 leads to impaired caveolae formation and altered downstream signaling, including reduced activation of ERK1/2 and AKT, as well as dysregulated SMAD2/3 phosphorylation downstream of TGF-beta. Consequently, loss of CAV2 perturbs integrin-mediated adhesion and Rho GTPase activity, affecting pathways such as MAPK/ERK, PI3K/AKT, JAK/STAT, and TGF-beta signaling.
In the HT29 colorectal cancer context, CAV2 knockout provides a powerful tool to dissect the role of caveolin-2 in intestinal epithelial malignancy. CAV2 has been implicated in colorectal cancer progression, and its deletion in HT29 cells allows interrogation of changes in proliferation, migration, invasion, and response to therapeutic agents. The polyclonal population captures a range of editing outcomes, enabling the study of heterogeneous loss-of-function effects that more closely mimic the in vivo tumor microenvironment. This model is particularly valuable for investigating the interplay between caveolin-dependent endocytosis, integrin signaling, and oncogenic pathways such as MAPK/ERK and PI3K/AKT cascades.
Research applications for these CAV2 knockout polyclonal HT29 cells include colorectal cancer modeling, caveolae biology, endocytosis studies, signal transduction research, and analysis of tumor microenvironment interactions. Representative experimental approaches encompass western blotting for CAV2 and phospho-ERK, RT-qPCR for mRNA quantification, immunofluorescence to visualize caveolae morphology, co-immunoprecipitation to assess CAV1 complex formation, and functional assays measuring cell migration, invasion, and proliferation. These cells are also suitable for flow cytometry-based surface marker analysis and drug sensitivity screens targeting CAV2-dependent pathways. For further information or to discuss custom applications, please contact Ascent Research.
